Long-term durability of Crohn's disease treatment with infliximab

Digestive Diseases and Sciences

Volumn 53, Issue 4, 2008, Pages 1033-1041

  Rudolph, Stephen J ^a,b   Weinberg, David I ^a,b   McCabe, Robert P ^a,b  

^a Minnesota Gastroenterology   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

6 Mercaptopurine; Antibodies; Azathioprine; Crohn's disease; Infliximab; Smoking

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FISTULA; FOLLOW UP; HUMAN; IMMUNOMODULATION; INCIDENCE; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SMOKING; SURVIVAL; T CELL LYMPHOMA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 40749152775     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9969-z     Document Type: Article

References (36)

1. Arnott ID, McNeill G, Satsangi J (2003) An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 17(12):1451-1457
2. Cadahia V, Garcia-Carbonero A, Vivas S et al (2004) Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice. Rev Esp Enferm Dig 96(6):369-74; 374-378
3. Laharie D, Salzmann M, Boubekeur H et al (2005) Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 29(2):145-149
4. Luna-Chadid M, Perez Calle JL, Mendoza JL et al (2004) Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig 96(6):379-81; 382-384
5. Parsi MA, Achkar JP, Richardson S et al (2002) Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123(3):707-713
6. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340(18):1398-1405
7. Rodrigo L, Perez-Pariente JM, Fuentes D, et al (2004) Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease. Rev Esp Enferm Dig 96(8):548-54; 554-558
8. Rutgeerts P, Feagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126(2):402-413
9. Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350(9):876-885
10. Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337(15):1029-1035
11. van Dullemen HM, van Deventer SJ, Hommes DW et al (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109(1):129-135
12. Wenzl HH, Reinisch W, Jahnel J et al (2004) Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 16(8):767-773
13. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH (2001) Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 31(3):146-150
14. Cohen RD, Tsang JF, Hanauer SB (2000) Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95(12):3469-3477
15. Farrell RJ, Shah SA, Lodhavia PJ et al (2000) Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95(12):3490-3497
16. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ (2001) Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96(3):722-729
17. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317):1541-1549
18. Rutgeerts P, D'Haens G, Targan S et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117(4):761-769
19. Hanauer SB, Wagner CL, Bala M et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2(7):542-553
20. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128(4):862-869
21. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR (2003) The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 98(10):2232-2238
22. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS (1980) Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302(18):981-987
23. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological A (2006) American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130(3):940-987
24. Baert F, Noman M, Vermeire S et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601-608
25. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552-1563
26. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124(4):917-924
27. Fefferman DS, Lodhavia PJ, Alsahli M et al (2004) Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis 10(4):346-351
28. Kinney T, Rawlins M, Kozarek R, France R, Patterson D (2003) Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 98(3):608-612
29. Vermeire S, Louis E, Carbonez A et al (2002) Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 97(9):2357-2363
30. Keshavarzian A, Mayer L, Salzberg B et al (2007) A multicenter retrospective experience of infliximab in Crohn's disease patients: Infusion reaction rates and treatment persistency. Gastroenterol Hepatol 3:381-390
31. Breuer-Katschinski BD, Hollander N, Goebell H (1996) Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 8(3):225-228
32. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP (1996) Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 110(2):424-431
33. Thomas GA, Rhodes J, Green JT (1998) Inflammatory bowel disease and smoking-a review. Am J Gastroenterol 93(2):144-149
34. Su C, Lichtenstein GR (2005) Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev 57(2):237-245
35. Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126(1):19-31
36. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN (2005) Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40(2):220-222